Astrazeneca’s Dr Anil Kukreja explains how Project Heartbeat can help prevent heart attacks


Anglo-Swedish pharmaceutical company AstraZeneca, which has gained popularity in India thanks to its COVID-19 vaccine Covishield, has teamed up with Bengaluru-based health technology startup Tricog for the Heartbeat project in the country.

In this edition of the Medicine Box season 5, CNBC-TV18’s Ekta Batra speaks with Dr Anil Kukreja, vice president of medical affairs and regulation at AstraZeneca to learn more about the project to ensure a diagnosis. early and precise of possible heart attacks. in patients from level 2 and 3 cities.

Dr Kukreja noted that early diagnosis and prompt treatment are key to preventing heart attacks. The project which has been piloted in eight centers across India, city level 2 patients can have their electrocardiogram (ECG) test read by qualified cardiologists.

The technology of the Heartbeat project was created with ECG machines and communicators. The communicator sends the ECG readings to a cardiologist who provides the diagnosis within minutes, explained Dr Kukreja.

“The aim is to reduce the ‘gate to needle’ and ‘gate to ball’ time,” said the senior AstraZeneca official, adding that they were trying to train medical professionals and technicians to ensure that Precise medications are delivered to patients on time.

Tune in to The Medicine Box Podcast to learn more.


About Author

Comments are closed.